Concordance between patient-reported outcomes and CTCAE clinician-reported toxicities during outpatient chemotherapy courses: a retrospective cohort study in routine care

门诊化疗期间患者报告结局与CTCAE临床医生报告毒性的一致性:一项常规护理中的回顾性队列研究

阅读:1

Abstract

BACKGROUND: Patient-reported outcomes (PROs) are increasingly used but often correlate poorly with physicians' assessment of adverse events. Yet, discordance has been associated with poorer prognosis. METHODS: Single-centre retrospective study of patient and physician assessment of five chemotherapy-induced toxicities (mucositis, nausea, vomiting, peripheral neuropathy, diarrhoea) in routine care. Electronic PRO (e-PRO)-Common Terminology Criteria for Adverse Events (CTCAE) questionnaires were administered between outpatient chemotherapy sessions, using an online telehealth program. PRO-CTCAE grades were converted to CTCAE scale using the published composite grade of PRO-CTCAE, and compared with CTCAE grading of toxicities by physicians. We calculated Cohen's weighted Kappa and counted discordances on severe (CTCAE grade >2) and milder (grade 2) toxicities. RESULTS: A total of 122 patients filled electronically 519 PRO-CTCAE e-questionnaires for which physicians had rated at least one corresponding CTCAE item. Agreement between patients' composite grades of PRO-CTCAE and clinicians CTCAE grades was moderate for four symptoms, and fair for one (κ between 0.23 and 0.43). The incidence of serious toxicity varied across symptoms, from 0.22% to 2.50% of questionnaires. Both patient and clinician scored a severe toxicity in only one case. Among 2076 symptom assessments, we counted 27 disagreements on severe toxicities (1.30%). CONCLUSION: Patient-physician agreement is imperfect, but severe toxicities are rare, including in PROs. PRO-CTCAE and CTCAE remain complementary, and e-PRO-CTCAE tools help monitor symptoms.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。